Acute Lymphoblastic Leukemia (ALL)

• Bone marrow biopsy and flow cytometry reports confirming B-cell or T-cell type and the percentage of blasts.
• Cytogenetic and molecular results, especially the Philadelphia chromosome (BCR-ABL1) and other high-risk changes.
• Minimal residual disease (MRD) results after induction, if available.
• Complete treatment record: chemotherapy protocol, doses, cycles completed and any central nervous system testing.
• HLA typing of the patient and potential related donors if transplant is being considered.

1. Which subtype and risk group does my leukaemia fall into, and why?
2. What was my MRD result, and how will it guide further treatment?
3. Am I a candidate for targeted therapy such as a tyrosine kinase inhibitor?
4. When would a transplant or CAR-T therapy be recommended instead of chemotherapy alone?
5. What are the effects on fertility, and can it be protected before treatment?
6. How will I be monitored for relapse after treatment ends?

Outlook varies widely by age and subtype. Most children are cured with modern chemotherapy, and long-term survival is high. In adults, remission is common but cure rates are lower, and relapse is the main concern. Outcomes depend on genetic risk, MRD response, age and fitness. CAR-T therapy and transplant offer a chance of long-term remission for relapsed or high-risk disease.